This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pfister, D. G. Articles by Zelefsky, M. J. Search for Related Content PubMed PubMed Citation Articles by Pfister, D. G. Articles by Zelefsky, M. J. Related Articles Related Editorial Social Bookmarking                            What's this?

Concurrent Cetuximab, Cisplatin, and Concomitant Boost Radiotherapy for Locoregionally Advanced, Squamous Cell Head and Neck Cancer: A Pilot Phase II Study of a New Combined-Modality Paradigm

From the Memorial Sloan-Kettering Cancer Center, New York, NY; and ImClone Systems Incorporated, Branchburg, NJ

Address reprint requests to David G. Pfister, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; e-mail: pfisterd{at}mskcc.org

PURPOSE: Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth factor receptor. Cetuximab has activity in squamous cell carcinoma and enhances both chemotherapy and radiotherapy. We conducted a pilot phase II study of a new combined-modality paradigm of targeted therapy (cetuximab) with chemoradiotherapy.

PATIENTS AND METHODS: Eligible patients had stage III or IV, M0, squamous cell head and neck cancer. Treatment included concomitant boost radiotherapy (1.8 Gy/d weeks 1 to 6; boost: 1.6 Gy 4 to 6 hours later weeks 5 to 6; 70 Gy total to gross disease), cisplatin (100 mg/m² intravenously weeks 1 and 4), and cetuximab (400 mg/m² intravenously week 1, followed by 250 mg/m² weeks 2 to 10).

RESULTS: Twenty-two patients were enrolled (median age, 57 years; range, 41 to 72 years; median Karnofsky status, 90%; range, 70% to 90%; oropharynx primary tumor, 59% of patients; T4, 36%; N2/3, 77%; stage IV disease, 86%). One patient did not receive study treatment because of an ineligible diagnosis. The severity of expected, acute toxicities was typical of concurrent cisplatin and radiotherapy alone. Grade 3 or 4 cetuximab-related toxicities included acne-like rash (10%) and hypersensitivity (5%). However, the study was closed for significant adverse events, including two deaths (one pneumonia and one unknown cause), one myocardial infarction, one bacteremia, and one atrial fibrillation. With a median follow-up of 52 months, the 3-year overall survival rate is 76%, the 3-year progression-free survival rate is 56%, and the 3-year locoregional control rate is 71%.

CONCLUSION: This regimen is not currently recommended outside of the clinical trial setting. Further investigation of its safety profile is needed. However, preliminary efficacy is encouraging, and further development of this targeted combined-modality paradigm is warranted.

Supported by ImClone Systems Incorporated, Branchburg, NJ.

Presented in part at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 3, 2003; and the 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 13-17, 2005.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• Treatment of Advanced Head and Neck Cancer: What Lessons Have We Learned?
  Barbara A. Conley
  JCO 2006 24: 1023-1025 [Full Text]

This article has been cited by other articles:

				M. Guglin, M. Aljayeh, S. Saiyad, R. Ali, and A. B. Curtis Introducing a new entity: chemotherapy-induced arrhythmia Europace, December 1, 2009; 11(12): 1579 - 1586. [Abstract] [Full Text] [PDF]

				K. Lang, M. Sussman, M. Friedman, J. Su, H. J. Kan, D. Mauro, E. Tafesse, and J. Menzin Incidence and Costs of Treatment-Related Complications Among Patients With Advanced Squamous Cell Carcinoma of the Head and Neck Arch Otolaryngol Head Neck Surg, June 1, 2009; 135(6): 582 - 588. [Abstract] [Full Text] [PDF]

				G. FOUNTZILAS, A. BAMIAS, A. KALOGERA-FOUNTZILA, G. KARAYANNOPOULOU, M. BOBOS, E. ATHANASSIOU, K. T. KALOGERAS, C. TOLIS, P. TSEKERIS, P. PAPAKOSTAS, et al. Induction Chemotherapy with Docetaxel and Cisplatin Followed by Concomitant Chemoradiotherapy in Patients with Inoperable Non-nasopharyngeal Carcinoma of the Head and Neck Anticancer Res, February 1, 2009; 29(2): 529 - 538. [Abstract] [Full Text] [PDF]

				K. K. Ang Multidisciplinary Management of Locally Advanced SCCHN: Optimizing Treatment Outcomes Oncologist, August 1, 2008; 13(8): 899 - 910. [Abstract] [Full Text] [PDF]

				N. Choong and E. Vokes Expanding Role of the Medical Oncologist in the Management of Head and Neck Cancer CA Cancer J Clin, January 1, 2008; 58(1): 32 - 53. [Abstract] [Full Text] [PDF]

				J. K. Salama, T. Y. Seiwert, and E. E. Vokes Chemoradiotherapy for Locally Advanced Head and Neck Cancer J. Clin. Oncol., September 10, 2007; 25(26): 4118 - 4126. [Full Text] [PDF]

				M. V. Karamouzis, J. R. Grandis, and A. Argiris Therapies Directed Against Epidermal Growth Factor Receptor in Aerodigestive Carcinomas JAMA, July 4, 2007; 298(1): 70 - 82. [Abstract] [Full Text] [PDF]

				B. A. Conley Treatment of Advanced Head and Neck Cancer: What Lessons Have We Learned? J. Clin. Oncol., March 1, 2006; 24(7): 1023 - 1025. [Full Text] [PDF]